Colibacillosis affects pigs worldwide, and is considered a major health problem due to its pathogenicity. The disease involves a high economic impact due to increase in mortality, stunting, poor feed conversion, and additional costs due to medication. Vaccination and antibiotic therapies are commonly used for treatment and control of colibacillosis. However, the levels of resistance observed in E. coli to commonly used antibiotics, has been increasing over time in most pig rearing areas.
Florfenicol resistance: Escherichia coli
Publications
Swine
The low rate of resistance development, the low prevalence of transferable resistance and the limited use of phenicols in veterinary medicine explain the continued high degree of Florfenicol susceptibility among swine bacterial isolates.
Download this article
Related products
The first intradermal needle-free vaccine against Mycoplasma hyopneumoniae and PCV2, all in one, in suspension for injection
Live vaccine against porcine reproductive and respiratory syndrome (PRRS), in injectable freeze-dried tablet
Purified recombinant verotoxin 2e against edema disease, in suspension for injection
Inactivated vaccine, against progressive and non progressive swine atrophic rhinitis, in injectable suspension.
Inactivated vaccine against neonatal colibacillosis and Clostridium infections in swine, in injectable suspension
Inactivated vaccine against Clostridioides difficile and Clostridium perfringens type A infections in swine, in injectable suspension.
Inactivated vaccine against porcine parvovirus and swine erysipelas, in injectable suspension
Inactivated vaccine against swine erysipelas, parvovirosis and leptospirosis, in injectable suspension
Live vaccine against Aujeszky’s disease gE negative strain, in injectable freeze-dried tablet
Inactivated vaccine against swine erysipelas, in injectable suspension
Inactivated porcine against porcine parvovirus, in injectable suspension
Inactivated vaccine against enzootic pneumonia, in injectable suspension
Related services
Smart Vaccination by HIPRA is a revolutionary concept that combines: A smart vaccine including RFID technology in its label, a vaccination device which ensures precision and efficiency, and a new world of digital solutions in HIPRAlink Vaccination. All these elements are developed internally by HIPRA.
In Swine, the HIPRA SMART VACCINATION is spearheaded by our innovative MHYOSPHERE® PCV ID and UNISTRAIN® PRRS vaccines, the needle-free intradermal device Hipradermic® and the professional veterinary app HIPRAlink® Vaccination.
An innovative service based on data analysis that facilitates decision-making in swine
HIPRA Stats is a data analysis service for animal production companies.
Hipradermic® is an advanced needle-free injection device with wireless connectivity for the intradermal vaccination of pigs.
HIPRA University offers high quality training programmes in strategic areas of interest for professionals
Access an advanced diagnostic service with maximum comfort and reliability
